Twitxy Saved

Bernie Marini

@Berninini

bsky.app/profile/bernin… Clinical Pharmacist Specialist #Heme #Leukemia. @UMichPharmacy Dad. Girls Hockey & Lacrosse Coach. Views my own
anchor.fm/wolverheme Joined November 2010
1K Following 2.6K Followers 4K Posts

Latest posts 5

Bernie Marini @Berninini
A really well done analysis (n=1923!). In ultra high risk pts, no benefit to HD MTX in preventing cns relapse. Authors did a good job w/propensity score analysis for possible confounders

This practice comes with serious risks & patient burden, and it doesn’t seem to help.
Papa Heme Verified account @Papa_Heme Jun 11
It’s about time we remove CNS ppx in DLBCL from the NCCN guidelines.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
View quoted post on X
1 replies 4 reposts 32 likes 7.3K views View on X
Bernie Marini @Berninini
This is a REALLY great outline of the data in the cilta-cel vs. bispecific in the 2nd line MM treatment debate!
Al Garfall @AlGarfall Jun 9
@Eddie_Cliff @NatRevClinOncol @rajshekharucms @ManniMD1 @DianaNrco Nice commentary. I mostly agree as I outlined in this friendly exchange with @Rfonsi1: rafaelfonseca.substack.com/p/rebuttal-to-…
Cilta-cel still has a role after bsAb or before in pts who prefer it and fully understand risk. There are still many data gaps.
View quoted post on X
Bernie Marini @Berninini
Young clinicians don’t need to make critical appraisal their primary academic focus, but it is a skill every clinician MUST learn as early as possible. No trial is perfect but understanding the implications of imperfections is 🔑.

And remember - critique trials, not people!
Vincent Rajkumar Verified account @VincentRK May 5
I know some have become experts at clinical appraisal and clinical trial critique. It’s important to have this dialogue and it helps physicians and patients understand the drawbacks of a given trial. But my advise to young investigators is to best not to make it your primary academic output.

Secondly, when critiquing it’s also worthwhile remembering that the investigators of trials may also fully aware of the issues but there are many barriers and often we have to choose between not doing a trial at all versus compromising. Perfect trials are not common; we can usually find some fault with almost all trials. So we must strive to avoid rudeness and condescension.

Third, try if possible to lead a clinical trial or at least get engaged with someone who leads trials and get a feel for the various stakeholders who have veto power during trial design, and more importantly the various competing priorities for what the trial seeks to accomplish, it will be easier to understand why a specific control arm was chosen, or a why a specific endpoint was chosen, even though you may think they are the wrong ones.
View quoted post on X